Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Bromide, Pyridostigmine
2. Mestinon
3. Pyridostigmine
1. 101-26-8
2. Mestinon
3. Regonol
4. Kalimin
5. Kalymin
6. 3-(dimethylcarbamoyloxy)-1-methylpyridinium Bromide
7. 3-((dimethylcarbamoyl)oxy)-1-methylpyridin-1-ium Bromide
8. Regonal
9. Mestinon Bromide
10. Pyridostigmini Bromidum
11. Pyridostigmine (bromide)
12. (1-methylpyridin-1-ium-3-yl) N,n-dimethylcarbamate;bromide
13. Nsc-679759
14. Nsc-758435
15. Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-, Bromide
16. Mls000028385
17. 3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium Bromide
18. Kvi301na53
19. Pyridinium, 3-[[(dimethylamino)carbonyl]oxy]-1-methyl-, Bromide
20. Ro 1-5130
21. 3-hydroxy-1-methylpyridinium Bromide Dimethylcarbamate
22. Ncgc00094324-02
23. 3-(((dimethylamino)carbonyl)oxy)-1-methylpyridinium Bromide
24. Smr000058605
25. Ro-1-5130
26. 3-(dimethylcarbamyloxy)-1-methylpyridinium Bromide
27. Dsstox_cid_3540
28. 1-methyl-3-hydroxypyridinium Bromide Dimethylcarbamate
29. Dsstox_rid_77069
30. Dsstox_gsid_23540
31. Dimethylcarbamic Acid Ester Of 3-hydroxy-1-methylpyridinium Bromide
32. Chembl812
33. Carbamic Acid, Dimethyl-, Ester With 3-hydroxy-1-methylpyridinium Bromide
34. Unii-19qm69hh21
35. 3-dimethylcarbamoyloxy-1-methylpyridinium Bromide;3-dimethylcarbamoyloxy-1-methylpyridinium Bromide
36. Cas-101-26-8
37. Piridostigmina Bromuro [dcit]
38. Ccris 6798
39. Piridostigmina Bromuro
40. Hsdb 3924
41. Sr-01000003072
42. Bromure De Pyridostigmine
43. Bromuro De Piridostigmina
44. Einecs 202-929-9
45. Pyridostigmini Bromidum [inn-latin]
46. Bromure De Pyridostigmine [inn-french]
47. 3-{[(dimethylamino)carbonyl]oxy}-1-methylpyridinium Bromide
48. Unii-kvi301na53
49. Bromuro De Piridostigmina [inn-spanish]
50. Mestinon-sr
51. Pyridinium, 3-[[(dimethylamino)carbonyl]oxy]-1-methyl-, Bromide (1:1)
52. Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-, Bromide (1:1)
53. Mestinon (tn)
54. Pyridostigminebromine
55. Mfcd00079283
56. Pyridinium, 3-hydroxyl-1-methyl-, Bromide, Dimethylcarbamate
57. Opera_id_420
58. 3-hydroxy-1-methylpyridinium Bromide Dimethylcarbamate (ester)
59. Pyridostigmine Bromide [usp:inn:ban:jan]
60. Schembl41147
61. Mls001074080
62. Spectrum1503240
63. Chebi:8666
64. 3-(dimethylaminocarbonyloxy)-1-methylpyridinium Bromide
65. Dtxsid9023540
66. Hms500k09
67. Hy-b0207a
68. Pyridostigmine Bromide (mestinon)
69. Hms1922m05
70. Hms2092p14
71. Hms2234d06
72. Hms3259m16
73. Hms3263o11
74. Hms3369p02
75. Hms3651g13
76. Hms3884m21
77. Pharmakon1600-01503240
78. Pyridostigmine Bromide [mi]
79. Bcp02148
80. Pyridostigmine Bromide [inn]
81. Pyridostigmine Bromide [jan]
82. Tox21_111266
83. Tox21_501035
84. Ccg-40306
85. Nsc679759
86. Nsc758435
87. Pyridinium, 3-hydroxy-1-methyl-, Bromide, Dimethylcarbamate (ester)
88. Pyridostigmine Bromide [hsdb]
89. S1608
90. Akos015895321
91. Pyridostigmine Bromide [mart.]
92. Tox21_111266_1
93. Ac-8143
94. Lp01035
95. Nc00581
96. Nsc 758435
97. Pyridostigmine Bromide [usp-rs]
98. Pyridostigmine Bromide [who-dd]
99. Pyridostigmine Bromide [who-ip]
100. Ncgc00015862-07
101. Ncgc00094324-01
102. Ncgc00094324-03
103. Ncgc00094324-04
104. Ncgc00261720-01
105. Pyridostigmine Bromide (jp17/usp/inn)
106. As-13164
107. Pyridostigmine Bromide [ep Impurity]
108. Pyridostigmine Bromide [orange Book]
109. Eu-0101035
110. Ft-0603307
111. P1339
112. Pyridostigmine Bromide [ep Monograph]
113. Sw199029-2
114. Pyridostigmine Bromide [usp Monograph]
115. Pyridostigmini Bromidum [who-ip Latin]
116. D00487
117. P 9797
118. T71526
119. Q-201644
120. Sr-01000003072-2
121. Sr-01000003072-4
122. Q26840825
123. 3-((dimethylcarbamoyl)oxy)-1-methylpyridin-1-iumbromide
124. Z1541632810
125. Pyridostigmine Bromide, European Pharmacopoeia (ep) Reference Standard
126. Pyridostigmine Bromide, United States Pharmacopeia (usp) Reference Standard
Molecular Weight | 261.12 g/mol |
---|---|
Molecular Formula | C9H13BrN2O2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 2 |
Exact Mass | 260.01604 g/mol |
Monoisotopic Mass | 260.01604 g/mol |
Topological Polar Surface Area | 33.4 Ų |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 183 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Mestinon |
PubMed Health | Pyridostigmine Bromide (By mouth) |
Drug Classes | Central Nervous System Agent, Immunological Agent, Nerve Gas Antidote |
Drug Label | Mestinon (pyridostigmine bromide) is an orally active cholinesterase inhibitor. Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its structural formula is:Mestinon is available in the following forms: Syru... |
Active Ingredient | Pyridostigmine bromide |
Dosage Form | Tablet, extended release; Tablet; Syrup; Injectable |
Route | Injection; Oral |
Strength | 180mg; 60mg/5ml; 5mg/ml; 60mg |
Market Status | Prescription |
Company | Valeant Pharm North; Valeant Pharm Intl; Valeant Pharms |
2 of 4 | |
---|---|
Drug Name | Pyridostigmine bromide |
PubMed Health | Pyridostigmine Bromide (By mouth) |
Drug Classes | Central Nervous System Agent, Immunological Agent, Nerve Gas Antidote |
Drug Label | Pyridostigmine bromide is an orally active, reversible cholinesterase inhibitor. Its chemical name is: 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate.CAS registration number is 101-26-8.Pyridostigmine bromide has a molecular formula of C9H13B... |
Active Ingredient | Pyridostigmine bromide |
Dosage Form | Tablet |
Route | Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Impax Labs |
3 of 4 | |
---|---|
Drug Name | Mestinon |
PubMed Health | Pyridostigmine Bromide (By mouth) |
Drug Classes | Central Nervous System Agent, Immunological Agent, Nerve Gas Antidote |
Drug Label | Mestinon (pyridostigmine bromide) is an orally active cholinesterase inhibitor. Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its structural formula is:Mestinon is available in the following forms: Syru... |
Active Ingredient | Pyridostigmine bromide |
Dosage Form | Tablet, extended release; Tablet; Syrup; Injectable |
Route | Injection; Oral |
Strength | 180mg; 60mg/5ml; 5mg/ml; 60mg |
Market Status | Prescription |
Company | Valeant Pharm North; Valeant Pharm Intl; Valeant Pharms |
4 of 4 | |
---|---|
Drug Name | Pyridostigmine bromide |
PubMed Health | Pyridostigmine Bromide (By mouth) |
Drug Classes | Central Nervous System Agent, Immunological Agent, Nerve Gas Antidote |
Drug Label | Pyridostigmine bromide is an orally active, reversible cholinesterase inhibitor. Its chemical name is: 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate.CAS registration number is 101-26-8.Pyridostigmine bromide has a molecular formula of C9H13B... |
Active Ingredient | Pyridostigmine bromide |
Dosage Form | Tablet |
Route | Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Impax Labs |
Cholinesterase Inhibitors; Parasympathomimetics
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
A QUATERNARY AMMONIUM ANTICHOLINESTERASE DRUG ...PRINCIPAL USE IS IN THE TREATMENT OF MYASTHENIA GRAVIS. ...
Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 842
DOSAGE: THE EQUIVALENT PARENTERAL DOSE OF...PYRIDOSTIGMINE IS APPROX 1/30TH OF THE ORAL DOSE.
Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 1029
PYRIDOSTIGMINE HAS A SLOWER ONSET (13 MIN) THAN EDROPHONIUM (3 MIN) OR NEOSTIGMINE (6-8 MIN), BUT A LONGER DURATION OF ACTION THAN EITHER. FOR THIS REASON, IT HAS BEEN RECOMMENDED FOR PATIENTS WITH RENAL IMPAIRMENT.
American Medical Association, AMA Department of Drugs. AMA Drug Evaluations. 5th ed. Chicago: American Medical Association, 1983., p. 424
For more Therapeutic Uses (Complete) data for PYRIDOSTIGMINE BROMIDE (9 total), please visit the HSDB record page.
BROMIDE SENSITIVITY OCCASIONALLY OCCURS.
Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 842
Maternal Medication usually Compatible with Breast-Feeding: Pyridostigmine: Reported Sign or Symptom in Infant or Effect on Lactation: None. /from Table 6/
Report of the American Academy of Pediatrics Committee on Drugs in Pediatrics 93 (1): 141 (1994)
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
ITS ONSET OF ACTION BY ORAL ROUTE IS ABOUT 320 MIN...ITS DURATION OF ACTION BY THE ORAL ROUTE IS USUALLY SOMEWHAT LONGER AND ABSORPTION IS LESS ERRATIC THAN NEOSTIGMINE, WHICH ARE ADVANTAGES.
Osol, A. (ed.). Remington's Pharmaceutical Sciences. 16th ed. Easton, Pennsylvania: Mack Publishing Co., 1980., p. 842
Plasma concn of pyridostigmine was determined in 2 nursing mothers who were receiving oral doses of pyridostigmine bromide, 120-300 mg daily. The drug was not detectable in infant plasma and there were no signs of drug effects in the infant.
Hardell LI et al; Pyridostigmine in human breast milk; Br J Clin Pharmacol 14 (Oct): 565-7 (1982)
PYRIDOSTIGMINE AND ITS QUATERNARY ALCOHOL ARE...THE PREDOMINANT ENTITIES FOUND IN URINE AFTER ADMIN OF THIS DRUG TO MAN.
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 108
After admin of pyridostigmine bromide (200 nmol/kg, iv) to human subjects, the disposition half-life was 0.6-1.78 min and terminal half-life was 14.81-37.01 min. Clearance was 9.3-26.5 ml/min/kg which was greater than the presumptive value for glomerular filtration rate and the vol of distribution was 246.5-833.9 ml/kg.
Calvey TN et al; Kinetics of intravenous pyridostigmine in man; Br J Clin Pharmacol 11 (4): 406-8 (1981)
...PHARMACOLOGICAL EFFECTS OF ANTICHOLINESTERASE AGENTS ARE DUE PRIMARILY TO PREVENTION OF HYDROLYSIS OF /ACH/ ACETYLCHOLINE BY ACHE /ACETYLCHOLINESTERASE/ @ SITES OF CHOLINERGIC TRANSMISSION. TRANSMITTER THUS ACCUMULATES, AND THE ACTION OF ACH /ACETYLCHOLINE/ THAT IS LIBERATED BY CHOLINERGIC IMPULSES OR THAT LEAKS FROM THE NERVE ENDING IS ENHANCED.
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 103
Following admin of pyridostigmine bromide to rats, erythrocyte acetylcholinesterase activity recovered only slowly due to the covalent nature of inhibition. The logarithm of the plasma concn of pyridostigmine bromide was linearly related to the increase in tibialis twitch tension due to facilitation of neuromuscular transmission.
Barber HE et al; The relationship between the pharmacokinetics, cholinesterase inhibition and facilitation of twitch tension of the quaternary ammonium anticholinesterase drugs, neostigmine, pyridostigmine, edrophonium and 3-hydroxyphenyltrimethylammonium; Br J Pharmacol 66 (4): 525-30 (1979)
Of 12 analogs of pyridostigmine prepared by reacting 2-substituted 3-pyridinols with the desired carbamoyl chloride 2-iodo-3-(dimethylcarbamoyloxy)pyridine methiodide was the most active inhibitor of acetylcholinesterase and butyrylcholinesterase. The progressive inhibition curves for AChE and BuChE are compared and related to ionic attraction and steric requirements of the inhibitors.
Millner OE Jr et al; Synthesis and enzymic evaluation of pyridostigmine analogs used to probe the active sites of acetylcholinesterase and butyrylcholinesterase; J Med Chem 17 (1): 13-8 (1974)
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15665
Submission : 2001-10-16
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-07
Pay. Date : 2013-02-19
DMF Number : 16035
Submission : 2002-06-26
Status : Active
Type : II
Certificate Number : CEP 2009-211 - Rev 01
Issue Date : 2023-11-17
Type : Chemical
Substance Number : 1255
Status : Valid
NDC Package Code : 46016-1012
Start Marketing Date : 2012-11-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Sungjin Exim Co., Ltd.
Registration Date : 2021-05-12
Registration Number : 20210512-211-J-632
Manufacturer Name : Procos SPA
Manufacturer Address : Viamatteotti 249, Cameri(Novara)28062 Italy
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39379
Submission : 2024-04-01
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-11-27
Pay. Date : 2020-09-29
DMF Number : 35024
Submission : 2020-08-15
Status : Active
Type : II
Date of Issue : 2022-11-18
Valid Till : 2025-09-30
Written Confirmation Number : WC-0455
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10593
Submission : 1993-11-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39637
Submission : 2024-03-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5505
Submission : 1984-07-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8952
Submission : 1991-01-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6939
Submission : 1987-04-20
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Pyridostigmine Bromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pyridostigmine Bromide, including repackagers and relabelers. The FDA regulates Pyridostigmine Bromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pyridostigmine Bromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pyridostigmine Bromide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pyridostigmine Bromide supplier is an individual or a company that provides Pyridostigmine Bromide active pharmaceutical ingredient (API) or Pyridostigmine Bromide finished formulations upon request. The Pyridostigmine Bromide suppliers may include Pyridostigmine Bromide API manufacturers, exporters, distributors and traders.
click here to find a list of Pyridostigmine Bromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pyridostigmine Bromide DMF (Drug Master File) is a document detailing the whole manufacturing process of Pyridostigmine Bromide active pharmaceutical ingredient (API) in detail. Different forms of Pyridostigmine Bromide DMFs exist exist since differing nations have different regulations, such as Pyridostigmine Bromide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pyridostigmine Bromide DMF submitted to regulatory agencies in the US is known as a USDMF. Pyridostigmine Bromide USDMF includes data on Pyridostigmine Bromide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pyridostigmine Bromide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pyridostigmine Bromide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pyridostigmine Bromide Drug Master File in Japan (Pyridostigmine Bromide JDMF) empowers Pyridostigmine Bromide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pyridostigmine Bromide JDMF during the approval evaluation for pharmaceutical products. At the time of Pyridostigmine Bromide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pyridostigmine Bromide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pyridostigmine Bromide Drug Master File in Korea (Pyridostigmine Bromide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pyridostigmine Bromide. The MFDS reviews the Pyridostigmine Bromide KDMF as part of the drug registration process and uses the information provided in the Pyridostigmine Bromide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pyridostigmine Bromide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pyridostigmine Bromide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pyridostigmine Bromide suppliers with KDMF on PharmaCompass.
A Pyridostigmine Bromide CEP of the European Pharmacopoeia monograph is often referred to as a Pyridostigmine Bromide Certificate of Suitability (COS). The purpose of a Pyridostigmine Bromide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Pyridostigmine Bromide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Pyridostigmine Bromide to their clients by showing that a Pyridostigmine Bromide CEP has been issued for it. The manufacturer submits a Pyridostigmine Bromide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Pyridostigmine Bromide CEP holder for the record. Additionally, the data presented in the Pyridostigmine Bromide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Pyridostigmine Bromide DMF.
A Pyridostigmine Bromide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Pyridostigmine Bromide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Pyridostigmine Bromide suppliers with CEP (COS) on PharmaCompass.
A Pyridostigmine Bromide written confirmation (Pyridostigmine Bromide WC) is an official document issued by a regulatory agency to a Pyridostigmine Bromide manufacturer, verifying that the manufacturing facility of a Pyridostigmine Bromide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pyridostigmine Bromide APIs or Pyridostigmine Bromide finished pharmaceutical products to another nation, regulatory agencies frequently require a Pyridostigmine Bromide WC (written confirmation) as part of the regulatory process.
click here to find a list of Pyridostigmine Bromide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pyridostigmine Bromide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pyridostigmine Bromide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pyridostigmine Bromide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pyridostigmine Bromide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pyridostigmine Bromide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pyridostigmine Bromide suppliers with NDC on PharmaCompass.
Pyridostigmine Bromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pyridostigmine Bromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pyridostigmine Bromide GMP manufacturer or Pyridostigmine Bromide GMP API supplier for your needs.
A Pyridostigmine Bromide CoA (Certificate of Analysis) is a formal document that attests to Pyridostigmine Bromide's compliance with Pyridostigmine Bromide specifications and serves as a tool for batch-level quality control.
Pyridostigmine Bromide CoA mostly includes findings from lab analyses of a specific batch. For each Pyridostigmine Bromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pyridostigmine Bromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Pyridostigmine Bromide EP), Pyridostigmine Bromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pyridostigmine Bromide USP).
LOOKING FOR A SUPPLIER?